ATG7 and hepatocellular carcinoma: Treatment of hepatoma cells with the antineoplastic tyrosine kinase inhibitor drug sorafenib inactivated mTORC1 resulting in increased accumulation of autophagosomes, LC3B II, and autophagic flux, whereas ATG7 knockdown sensitized hepatoma cells to sorafenib [109].